Michael Ulz
Morgan Stanley, Research Division
All right. Good afternoon, everyone, and thanks for joining us at the Morgan Stanley Global Healthcare Conference. I’m Mike Ulz, one of the biotech analysts here, and it’s my pleasure to introduce Harith Rajagopalan, CEO of Fractyl Health. Just as a reminder, the format for today is a fireside chat. So if anyone has a question, please raise your hand, and we’ll make sure we address it.
But before we get started, I just need to read a quick disclosure. Before we get — for disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative.
And with that, I’ll turn it over to you, Harith, to maybe make some introductory comments, and then we can go into the Q&A.
Harith Rajagopalan
Co-Founder, CEO & Director
Sure. So my name is Harith Rajagopalan. I’m the Co-Founder and CEO of Fractyl. Thanks for having us, Mike. We are developing Revita, duodenal mucosal resurfacing for post GLP-1 weight maintenance. We have pivotal data coming in early Q4, just several weeks away for potentially the first therapeutic option that has the potential to deliver a durable metabolic reset for people with obesity and type 2 diabetes.
What that means is the potential for long-lasting clinical benefits in both weight and metabolic parameters even in the absence of ongoing medical therapy. The reason this matters so much is because, as everyone knows, GLP-1s have totally transformed the treatment landscape in obesity, diabetes and metabolic disease. We have nearly 30 million Americans